Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
2023年1月4日 - 2:10AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
under
the Securities Exchange Act of 1934
For
the month of January 2023
Commission
File Number: 001-40106
4D
pharma plc
(Translation
of Registrant’s name into English)
5th
Floor, 9 Bond Court
Leeds
LS1
2JZ
United
Kingdom
Tel:
+44 (0) 113 895 013
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F☒ Form 40-F
☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
On
December 30, 2022, 4D pharma plc (the “Company,” “4D,” “4D pharma,” “we,” “us”
or “our”) issued a press release entitled “4D pharma Announces an Update on Administration and Suspension of Trading”
regarding a circular being posted to the Company’s shareholders on December 30, 2022, which contains a notice of a General Meeting
to be held on January 16, 2023.
A
copy of the press release and a copy of the circular are attached as Exhibit 99.1 and Exhibit 99.2, respectively, to this current report
on Form 6-K and are incorporated by reference herein. This press release and circular are each incorporated by reference into the registration
statements on Form F-3 (File No. 333-263372 and File No. 333-264419) of 4D pharma plc, filed with the U.S. Securities and Exchange Commission,
to be a part thereof from the date on which this press release and circular are submitted, to the extent not superseded by documents
or reports subsequently filed or furnished.
INDEX
TO EXHIBITS
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
|
4D
pharma plc |
|
|
Date:
January 3, 2023 |
/s/
James Clark |
|
James
Clark |
|
Administrator |
4D Pharma (NASDAQ:LBPS)
過去 株価チャート
から 5 2024 まで 6 2024
4D Pharma (NASDAQ:LBPS)
過去 株価チャート
から 6 2023 まで 6 2024